The trend in liver disease-related mortality in individuals with HIV has changed, with a reduction in the incidence of viral hepatitis-related deaths and an increase in non-alcoholic fatty liver disease (NAFLD)-related deaths, according to a study presented at the International Liver Congress™ (ILC 2019).
Patients with non-alcoholic steatohepatitis (NASH) may benefit from treatment with a 25 mg/day dose of obeticholic acid, according to the interim analysis of the phase III REGENERATE* study presented at the International Liver Congress™ (ILC 2019).
Adults with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) who progress to advanced liver disease have an elevated risk of mortality compared with non-progressors, according to two separate studies conducted in Germany and France and presented at the International Liver Congress™ (ILC 2019).
Individuals with imaging-defined or biopsy-proven nonalcoholic fatty liver disease are likely to have a self‐reported history of osteoporotic fractures but not a low bone mineral density, according to a meta-analysis.
The patient profiles of individuals diagnosed with hepatocellular carcinoma (HCC) vary depending on whether the cause of HCC is hepatitis B virus (HBV) infection or cryptogenic, a Singapore study found.
Complete resolution of nonalcoholic fatty liver disease (NAFLD) is highly likely to occur following sustained weight loss in obese patients who have undergone bariatric surgery, although there are still some who may develop new or worsened features of NAFLD, a study has shown.
Microbial therapies, such as prebiotics and probiotics, show potential in patients with nonalcoholic fatty liver disease, yielding reductions in body mass index, hepatic enzymes, serum cholesterol and triglycerides, a study has shown.
Coeliac disease patients have a threefold risk of nonalcoholic fatty liver disease (NAFLD) despite adherence to a gluten-free diet, a study has found. This risk is especially higher in the lean population.
Co-therapy with proton pump inhibitors (PPIs) in patients receiving low-dose anticoagulation and/or aspirin for stable cardiovascular disease confers no benefit for upper gastrointestinal events but may reduce bleeding due to gastroduodenal lesions, a study has shown.
Proton pump inhibitor therapy, particularly with pantoprazole, does not reduce upper gastrointestinal bleeding events in patients taking low-dose anticoagulation/aspirin treatment, reports a recent study.
Colonoscopy in patients under propofol sedation may be enhanced with the water exchange (WE) method by significantly improving colon cleanliness and overall adenoma detection rate (ADR), suggests a recent study.